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RAPID RECOMMENDATIONS
Transcatheter or surgical aortic valve replacement for
patients with severe, symptomatic, aortic stenosis at
low to intermediate surgical risk: a clinical practice
guideline
In patients with symptomatic severe aortic stenosis but at lower risk of perioperative death, how do
minimally invasive techniques compare with open surgery? Prompted by a recent trial, an expert
panel produced these recommendations based on three linked rapid systematic reviews
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A randomised controlled trial of transcatheter aortic valve
insertion (TAVI) versus surgical aortic valve replacement
(SAVR) in patients with severe aortic stenosis was published
in April 2016. The Partner 2 trial included 2032 people at
intermediate surgical risk and favoured TAVI over open SAVR
at two years for some outcomes.1 It had the potential to change
practice.
Before the availability of TAVI, the only effective treatment
for symptomatic severe aortic stenosis was SAVR with
mechanical or bioprosthetic valves (fig 1⇓). In practice, patients
offered mechanical valves tend to be younger and must accept
lifelong anticoagulation. The minimally invasive option, TAVI,
was developed for patients who are unfit for surgery, in whom
its use is recommended bymajor US and European guidelines.2 3
Severe aortic stenosis affects approximately 3 in 100 people
over the age of 75 years.4 Patients typically experience
symptoms of heart failure and reduced quality of life. Without
aortic valve replacement, life expectancy is typically 50% at
two years, with escalation of heart failure and reduced quality
of life.5 These recommendations are for patients with symptoms
and severe aortic stenosis: patients without symptoms or with
milder disease are not considered here. Box 1 shows the linked
articles in this BMJ Rapid Recommendations cluster.
How the recommendations were created
The international expert panel included front line and
intervention cardiologists, a heart surgeon, internists, a general
practitioner, methodologists, and people with lived experience
of the condition (see list of panel members). To avoid bias, we
excluded people with a professional, academic, or financial
conflict of interest that we judged as excessive (see online
methods supplement, competing interests statement, and
appendix of interests of the panel members).
The panel followed standards for trustworthy guidelines and
used the GRADE methodology to critically appraise the
evidence and to create recommendations.6-8Whenmoving from
evidence to recommendations, the panel integrated information
on benefits and harms of treatment alternatives, quality of
evidence, and values and preferences of patients as well as
acceptability, feasibility, and resources (see box 1). Estimates
of absolute effects are derived from relative effect estimates
from the systematic review coupled with the best population
estimates of baseline risks derived from a linked systematic
review of observational studies.9 We label recommendations
for or against each alternative as either weak or strong (see
infographic).
The evidence
A linked systematic review and meta-analysis combines the
data from the Partner 2 trial with three other trials (see fig 2⇓).
It pools data on 3128 patients with symptomatic severe aortic
stenosis at low or moderate risk of perioperative death, typically
followed for two years.1-14
Compared with SAVR, transfemoral TAVI reduced mortality
and stroke, life threatening bleeds, atrial fibrillation, and acute
kidney injury at two years, but increased heart failure, major
vascular complications, pacemaker insertion, and need for aortic
valve reintervention within 2 years (see infographic).10 In
contrast, transapical TAVI may increase mortality and stroke
compared with the surgical approach. The results for mortality,
stroke, and acute kidney injury were based on a subgroup
analysis for transfemoral versus transapical approach, deemed
credible by the review authors according to specific criteria.15
Estimates of baseline risk for most outcomes came from a linked
systematic review on prognosis for patients undergoing SAVR.9
The panel were reasonably confident that the absolute effect
sizes for the short term benefit and harm of TAVI and SAVR
were true and accurate estimates (that is, overall moderate
certainty according to GRADE). But the panel were very
uncertain about the long term durability of the valves used in
TAVI, particularly with respect to their recommendations in
younger patients with a longer predicted life expectancy. The
low certainty in the estimated long term re-intervention rate
after TAVI of approximately 27 in 100 people reflects an
absence of published follow-up studies beyond five years.
The linked systematic review on values and preferences yielded
extremely limited evidence to inform the recommendations,
particularly their strength.16 There are no studies on patients
deciding between TAVI and SAVR, although one study
evaluated patient preferences and values when deciding whether
to undergo SAVR (versus no surgery).16 17 One study identified
multiple biomedical, functional, social, and environmental
factors influencing patients’ decisions to undergo assessment
for TAVI.18Overall, there is evidence of variability in individual
values and preferences, highlighting the need for shared decision
making, particularly for patients aged between 65 and 85 years.
Practical considerations
Perioperative risk is typically assessed by expert cardiovascular
teams. Validated risk scores such as the STS-PROM are
available online (www.riskcalc.sts).
Type of device and TAVI approach may vary: balloon
expandable and self expanding devices can be used via
This BMJ Rapid Recommendations article is one of a series that provides clinicians with trustworthy recommendations for potentially practice
changing evidence. BMJ Rapid Recommendations represent a collaborative effort between the MAGIC group (www.magicproject.org) and The
BMJ. A summary is offered here and the full version including decision aids is on the Magic app (www.magicapp.org), for all devices in multilayered
formats. Those reading and using these recommendations should consider individual patient circumstances such as frailty, overall life expectancy,
and relevant comorbidity, and their values and preferences. We encourage adaptation of recommendations to allow contextualisation of
recommendations and to reduce duplication of work. Those considering use or adaptation of content may go to MAGICapp to link or extract its
content or contact The BMJ for permission to reuse content in this article. Series adviser Rafael Perera-Salazar
Data supplements on bmj.com (see http://www.bmj.com/content/354/bmj.i5085?tab=related#datasupp)
Infographic: Summary of recommendations and evidence
Appendix 1: Full list of authors’ declarations of interests
Appendix 2: Methodology for development of BMJ Rapid Recommendations
Appendix 3: The full information available on the MAGICapp
Appendix 4: Rapid Recommendation panel members
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What you need to know
• New trial evidence confirms that transcatheter aortic valve insertion (TAVI), initially developed for patients with severe aortic stenosis
who were unfit for surgical aortic valve replacement (SAVR), can be offered also to patients at low to intermediate surgical risk
• Long term durability of TAVI valves remains highly uncertain
• Age stratified recommendations reflect that TAVI is probably preferable to those over 75 years old, whereas SAVR is likely preferable
to those under 75 years
Box 1: Linked articles in this BMJ Rapid Recommendations cluster
• Siemieniuk RA, Agoritsas T, Manja V, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic
stenosis at low and intermediate risk: systematic review and meta-analysis. BMJ 2016;354:i5130. doi:10.1136/bmj.i5130
• Foroutan F, Guyatt GH, O’Brien K, et al. Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe
symptomatic aortic stenosis: systematic review of observational studies. BMJ 2016;354:i5065. doi:10.1136/bmj.i5065
• Lytvyn L, Guyatt GH, Manja V, et al. Patient values and preferences on transcatheter or surgical aortic valve replacement therapy for
aortic stenosis: a systematic review. BMJ Open 2016;6:e014327. doi:10.1136/bmjopen-2016-014327
• Editorial: Siemieniuk RA, Macdonald H, Agoritsas T, Guyatt GH, Vandvik PO. Introduction to BMJ Rapid Recommendations. BMJ
2016;354:i5191, doi:10.1136/bmj.i5191.
• Magic App (www.magicapp.org/public/guideline/aEeKpL)
– Expanded version of the results with multilayered recommendations, evidence summaries, and decision aids for use on all devices
transfemoral, subclavian, direct aortic, transcarotid, or
transapical (balloon only) routes.
Fig3⇓ lists issues that may influence a person’s choice of
procedure. These are further detailed in MAGICapp within the
consultation decision aids that provide all desirable and
undesirable consequences of treatment options.
Costs and resources
There are no cost effectiveness data for patients at low to
intermediate surgical risk considering TAVI versus SAVR. Both
procedures are resource demanding and require an experienced
cardiovascular team (table 1⇓). In general, TAVI devices are
more expensive than surgery, but this extra cost may be partially
offset by a slightly shorter hospital stay and less need for
post-discharge rehabilitation.
Future research
Future recommendations and guidelines would benefit from
studies that answer the following questions
• Qualitative or survey study. What are the values and
preferences of patients deciding between TAVI and SAVR,
particularly with respect to uncertain durability of TAVI
devices, the desire to avoid open heart surgery, and
post-procedure pain and recovery time?
• What is the durability of the TAVI valves beyond five
years?
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Table
Table 1| Facilities and teams required for transcatheter aortic valve insertion (TAVI) versus surgical aortic valve replacement (SAVR)*
Extent of requirement
Resource SAVRTAVI
+++++Heart team
N/A+++Surgical backup
++++++Cardiac anaesthesia
—++Hybrid suite
++++Catheterisation laboratory facility
+++++Intensive care unit
+/−++Coronary care unit
5-102-5Length of hospital stay (days)†
+++++Rehabilitation
++++Follow-up clinic
*Based on panel expert members experience from practice.
†Estimates reflect current practice according to content experts on the panel. Length of stay was considerably longer in the trials (see infographic).
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Figures
Fig 1 Flowchart for management of severe aortic stenosis (AS). Coloured boxes represent the recommendations covered
by this article. AVR=aortic valve replacement, SAVR=surgical aortic valve replacement, TAVI=transcatheter aortic valve
insertion
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Fig 2 Patient and trial characteristics in the four trials of the linked meta-analysis10
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Fig 3 Practical considerations that may influence a patient’s choice of procedure. For a complete list, see decision aids in
the MAGICapp (www.magicapp.org/public/guideline/aEeKpL)
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